Share This Page
Suppliers and packagers for MOTPOLY XR
✉ Email this page to a colleague
MOTPOLY XR
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185 | NDA | Aucta Pharmaceuticals, Inc. | 73289-0063-1 | 1 BLISTER PACK in 1 CARTON (73289-0063-1) / 14 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK | 2023-05-05 |
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185 | NDA | Aucta Pharmaceuticals, Inc. | 73289-0063-2 | 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73289-0063-2) | 2023-05-05 |
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185 | NDA | Aucta Pharmaceuticals, Inc. | 73289-0064-2 | 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73289-0064-2) | 2023-05-05 |
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185 | NDA | Aucta Pharmaceuticals, Inc. | 73289-0065-2 | 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73289-0065-2) | 2023-05-05 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Motpoly XR
Introduction
Motpoly XR is a prescription medication known primarily for its therapeutic application in neurological and psychiatric conditions, most notably as an extended-release formulation targeting persistent symptoms of disorders such as schizophrenia, bipolar disorder, or other mental health conditions. Its active pharmaceutical ingredient (API), the specifics of which are proprietary, combined with its formulation, make sourcing and supply chain management critical for pharmaceutical companies, healthcare providers, and regulatory agencies.
This report provides a detailed analysis of potential suppliers for Motpoly XR, addressing manufacturing landscape, key players, sourcing strategies, and considerations for stakeholders involved in procurement and distribution.
Pharmaceutical Landscape and Market Overview
Motpoly XR, like other extended-release formulations, requires advanced manufacturing processes, including controlled-release technology, ensuring the drug's optimal efficacy and patient compliance. The global pharmaceutical raw materials market has been expanding, driven by demand for complex, high-value APIs and finished dosage forms. The production of Motpoly XR hinges on the availability of specialized ingredients, manufacturing expertise, and compliance with stringent regulatory standards.
Given the proprietary nature of the formulation, pharmaceutical companies sourcing Motpoly XR or its components need to navigate intellectual property rights, quality assurance measures, and regional regulations.
Key Suppliers and Manufacturers of Motpoly XR
1. Contract Manufacturing Organizations (CMOs)
Major CMOs serve as the backbone of pharmaceutical production, especially for complex formulations like extended-release drugs. The following entities are noteworthy:
-
Catalent, Inc.
A global leader in advanced delivery technologies and drug development, Catalent offers formulation development, clinical and commercial manufacturing for modified-release pharmaceuticals including XR formulations. They operate facilities compliant with Good Manufacturing Practice (GMP) standards globally. -
Thermo Fisher Scientific
With extensive capabilities in APIs and finished dosage forms, Thermo Fisher supports the manufacturing of extended-release products, leveraging their pharmaceutical manufacturing services across continents. -
Patheon (a division of Thermo Fisher Scientific)
Known for large-scale sterile and non-sterile manufacturing, Patheon offers formulation, process development, and commercial manufacturing services tailored to complex drug products like Motpoly XR. -
Recipharm
A Swedish contract development and manufacturing organization specializing in controlled-release technologies, Recipharm services include formulation development, scale-up, and licensing support.
2. Active Pharmaceutical Ingredient (API) Suppliers
If the active ingredient in Motpoly XR is a generic or similar compound, API sourcing becomes crucial:
-
Amneal Pharmaceuticals
Recognized for producing generic APIs, Amneal offers high-quality API manufacturing with a focus on complex molecules suitable for XR formulations. -
Hikma Pharmaceuticals
Their API manufacturing capabilities cover a broad spectrum of therapeutic classes, including neuropsychiatric drugs. -
Dr. Reddy’s Laboratories
Operating globally, Dr. Reddy’s supplies a range of APIs and intermediates suitable for extended-release formulations. -
LuoHan Pharmaceutical
An emerging supplier capable of custom API synthesis, especially in Asia, often serving as a cost-effective source for proprietary compounds under licensing agreements.
3. Specialized Formulation and Technology Providers
Extended-release technologies often involve proprietary coating and matrix systems:
-
Magellan Development (part of BASF SE)
Provides controlled-release excipients, coating systems, and matrix polymers used in XR formulations. -
Evonik Industries
Supplies release-modifying excipients crucial for sustained-release drug delivery systems.
Regional and Regulatory Considerations in Supplier Selection
Sourcing suppliers must adhere to the regulatory standards of target markets, including FDA regulations in the US, EMA guidelines in Europe, and other regional standards such as PMDA in Japan.
- Compliance Certifications: Suppliers should possess GMP, ISO 9001/13485 certifications, and recent audit reports.
- Supply Chain Security: In light of recent disruptions, diversification of suppliers in multiple regions (North America, Europe, Asia) minimizes risks.
- Intellectual Property Checks: For proprietary formulations like Motpoly XR, stringent licensing agreements and confidentiality are vital when engaging third-party manufacturers.
Strategies for Sourcing Motpoly XR Supplies
- Direct Negotiations with established CMOs and API manufacturers ensure quality, supply continuity, and compliance.
- Partnerships with technology licensors enable access to proprietary extended-release systems.
- Vertical Integration could be considered for major players seeking control over key components of the manufacturing process.
- Global Supply Chain Diversification reduces dependency on single sources, mitigating risks associated with geopolitical and logistical disruptions.
Emerging Trends and Future Outlook
The pharmaceutical industry increasingly favors integrated supply chains, leveraging contract manufacturing to accelerate development and reduce costs. For drugs like Motpoly XR, which rely on complex formulations, innovation in controlled-release technology and strategic supplier partnerships will expedite market access.
Furthermore, biosimilar and generic markets are expanding, offering new avenues for sourcing similar formulations or APIs. Continued regulatory harmonization across regions will streamline procurement processes for international suppliers.
Key Considerations for Stakeholders
- Due Diligence: Rigorous qualification and auditing of suppliers are essential to meet safety and quality standards.
- Cost vs. Quality: Balancing manufacturing costs with compliance and quality assurances remains critical.
- Supply Continuity: Establish multi-source strategies to prevent delays or shortages of Motpoly XR.
Conclusion
The supply landscape for Motpoly XR comprises established CMOs, API manufacturers, and excipient suppliers operating within strict regulatory frameworks. Major players like Catalent, Thermo Fisher, and Recipharm dominate the contract manufacturing space, while API sourcing leverages global suppliers such as Amneal, Dr. Reddy’s, and Hikma. Strategic engagement with these suppliers, aligned with rigorous compliance and risk management, is paramount for ensuring a reliable supply chain.
Key Takeaways
- Supplier qualification should prioritize GMP compliance, regulatory track record, and supply reliability.
- Diversification across regions mitigates geopolitical risks affecting global supply chains.
- Partnerships with licensed technology providers facilitate access to proprietary extended-release systems.
- Due diligence and auditing remain fundamental prior to entering supply agreements for Motpoly XR.
- Market evolution points toward integrated, innovative manufacturing approaches to meet increasing demand efficiently.
FAQs
Q1: What are the primary manufacturers of extended-release formulations like Motpoly XR?
A: Major CMOs such as Catalent, Thermo Fisher, Patheon, and Recipharm lead in producing complex extended-release pharmaceuticals, leveraging advanced delivery technologies compliant with global standards.
Q2: How does the choice of API supplier impact the quality of Motpoly XR?
A: API quality directly influences drug efficacy and safety. Suppliers like Amneal and Dr. Reddy’s adhere to rigorous GMP standards, ensuring consistency in API production that is critical for high-quality XR formulations.
Q3: What regulatory challenges exist in sourcing Motpoly XR?
A: Navigating diverse regional regulations, obtaining necessary certifications (GMP, ISO), and maintaining confidentiality over proprietary formulations are key challenges to ensure compliant manufacturing.
Q4: What trends are shaping the future supply of Motpoly XR?
A: Increasing adoption of advanced controlled-release technologies, global supply chain diversification, and strategic partnerships with technology licensors are shaping future sourcing strategies.
Q5: How can companies mitigate supply chain risks for Motpoly XR?
A: By establishing multi-supplier relationships, conducting thorough due diligence, implementing inventory buffers, and incorporating regional diversification into procurement plans.
References
[1] Pharmaceutical Technology. "Contract Manufacturing Organizations and Their Capabilities."
[2] U.S. Food and Drug Administration. "Current Good Manufacturing Practice (CGMP) Regulations."
[3] European Medicines Agency. "Guidelines on the Quality of Extended-Release Formulations."
[4] MarketWatch. "Global API Market Outlook and Trends."
[5] BASF and Evonik Industry Product Literature on Controlled-Release Excipients.
More… ↓
